Relevant bibliographies by topics / PHARMA] Life Sciences

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'PHARMA] Life Sciences'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'PHARMA] Life Sciences.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "PHARMA] Life Sciences"

1

Jakobi, Rolf. "Risikomanagement in Pharma und Life-Sciences." Nachrichten aus der Chemie 51, no. 9 (September 2003): 946–47. http://dx.doi.org/10.1002/nadc.20030510920.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ratzel, Rudolf. "Stief/Bromm (Hrsg.), Vertragshandbuch Pharma und Life Sciences." GesundheitsRecht 21, no. 2 (February 1, 2022): 135–36. http://dx.doi.org/10.9785/gesr-2022-210222.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Siegismund, Daniel, Vasily Tolkachev, Stephan Heyse, Beate Sick, Oliver Duerr, and Stephan Steigele. "Developing Deep Learning Applications for Life Science and Pharma Industry." Drug Research 68, no. 06 (January 16, 2018): 305–10. http://dx.doi.org/10.1055/s-0043-124761.

Full text
Abstract:
AbstractDeep Learning has boosted artificial intelligence over the past 5 years and is seen now as one of the major technological innovation areas, predicted to replace lots of repetitive, but complex tasks of human labor within the next decade. It is also expected to be ‘game changing’ for research activities in pharma and life sciences, where large sets of similar yet complex data samples are systematically analyzed. Deep learning is currently conquering formerly expert domains especially in areas requiring perception, previously not amenable to standard machine learning. A typical example is the automated analysis of images which are typically produced en-masse in many domains, e. g., in high-content screening or digital pathology. Deep learning enables to create competitive applications in so-far defined core domains of ‘human intelligence’. Applications of artificial intelligence have been enabled in recent years by (i) the massive availability of data samples, collected in pharma driven drug programs (=‘big data’) as well as (ii) deep learning algorithmic advancements and (iii) increase in compute power. Such applications are based on software frameworks with specific strengths and weaknesses. Here, we introduce typical applications and underlying frameworks for deep learning with a set of practical criteria for developing production ready solutions in life science and pharma research. Based on our own experience in successfully developing deep learning applications we provide suggestions and a baseline for selecting the most suited frameworks for a future-proof and cost-effective development.
APA, Harvard, Vancouver, ISO, and other styles
4

Clemow, D. B., C. Sapin, T. Hibi, M. C. Dubinsky, S. Vermeire, S. Schreiber, T. H. Gibble, et al. "A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (March 1, 2023): 31–32. http://dx.doi.org/10.1093/jcag/gwac036.186.

Full text
Abstract:
Abstract Background Ulcerative colitis (UC) can result in a high prevalence of bowel movement urgency (BU), significantly reducing patient quality of life. Purpose Early BU improvement association with later clinical endpoint improvements was examined in moderately-to-severely active UC patients (pts) treated with mirikizumab (miri). Method BU was evaluated in Phase 3 randomized placebo (PBO)-controlled 12-week induction (LUCENT-1, NCT03518086) and 40-week maintenance (LUCENT-2, NCT03524092) trials with miri. Pts received IV miri 300mg or PBO during induction. Week (W)12 miri responders were rerandomized at LUCENT-2 baseline (BL) to subcutaneous miri 200mg or PBO. BU was measured with 11-point Urgency Numeric Rating Scale (UNRS) from 0 (no urgency) to 10 (worst possible). Pts’ UNRS scores were an average from 7 consecutive days prior to visit. Association of pts with BU Clinically Meaningful Improvement (CMI) or BU remission between BL and W4 with the proportion of pts achieving clinical response, and clinical, endoscopic, or symptomatic remission at end of W12 was assessed. For pts who achieved clinical response at W12, the analyses were repeated for the end of maintenance based on W12 BU status. Logistic regression models with treatment, urgency (BU CMI or BU Remission), treatment-by-urgency group interaction, and stratification factors were fitted to examine the association between early urgency improvement and later clinical endpoints. Result(s) Treatment-by-urgency group interactions were not statistically significant across clinical outcomes for induction and maintenance. For induction, treatment and urgency status were statistically significant. Pts experiencing BU CMI or BU remission at W4 were consistently more likely to achieve clinical response, and clinical, endoscopic, or symptomatic remission at W12 for both treatment groups. For remission, only treatment main effect was statistically significant. Among miri induction clinical responders (an enriched population), BU CMI or BU Remission at end of induction (W12) was not associated with later maintenance efficacy outcomes (W52). Miri-treated pts achieved higher rates of clinical response, and clinical, endoscopic, or symptomatic remission at W52 than with PBO regardless of BU CMI or BU Remission at W12 (Table). Image Conclusion(s) Early BU Improvement, CMI or Remission, was associated with better clinical outcomes during induction for miri and PBO pts, showing BU is a sensitive predictor of early clinical outcomes. Among miri induction responders, miri consistently provided better maintenance of response and remission rates than PBO. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Eli Lilly and Company Disclosure of Interest D. Clemow Employee of: Eli Lilly and Company, C. Sapin Employee of: Eli Lilly and Company, T. Hibi Grant / Research support from: AbbVie, ActivAid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan K.K., Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical K.K., JMDC, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan, and Takeda, Consultant of: AbbVie, Apo Plus Station, Bristol Myers Squibb, Celltrion, EA Pharma, Eli Lilly and Company, Gilead Sciences, Janssen, Kyorin, Mitsubishi Tanabe Pharma, Nichi-Iko Pharmaceutical, Pfizer, Takeda, and Zeria Pharmaceutical, Speakers bureau of: AbbVie, Aspen Japan K.K., Ferring Pharmaceuticals, Gilead Sciences, Janssen, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, and Takeda, M. Dubinsky Shareholder of: Trellus Health, Grant / Research support from: AbbVie, Janssen, Pfizer, and Prometheus Biosciences, Consultant of: AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Genentech, Gilead Sciences, Janssen, Pfizer, Prometheus Therapeutics and Diagnostics, Takeda, and UCB Pharma, S. Vermeire Consultant of: AbbVie, Arena Pharmaceuticals, Avaxia Biologics, Boehringer Ingelheim, Celgene, Dr. Falk Pharma, Ferring Pharmaceuticals, Galapagos NV, Genentech/Roche, Gilead Sciences, Hospira, Janssen, Mundipharma, Merck Sharp & Dohme, Pfizer, ProDigest, Progenity, Prometheus Therapeutics and Diagnostics, Robarts Clinical Trials, Second Genome, Shire, Takeda, Theravance Biopharma, and Tillots Pharma AG, Speakers bureau of: AbbVie, Dr. Falk Pharma, Ferring Pharmaceuticals, Galapagos NV, Genentech/Roche, Gilead Sciences, Janssen, Pfizer, Robarts Clinical Trials, and Takeda, S. Schreiber Grant / Research support from: personal fees and/or travel support from: AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly and Company, Dr. Falk Pharma, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos NV, Gilead Sciences, I-MAB Biopharma, Janssen, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Protagonist Therapeutics, Provention Bio, Roche, Sandoz/Hexal, Shire, Takeda, Theravance Biopharma, and UCB Pharma, T. Gibble Employee of: Eli Lilly and Company, L. Peyrin-Biroulet Grant / Research support from: AbbVie, Fresenius Kabi, Merck Sharp & Dohme, and Takeda, Consultant of: AbbVie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly and Company, Enthera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos NV, Genentech, Gilead Sciences, Gossamer Bio, InDex Pharmaceuticals, Inotrem, Janssen, Merck Sharp & Dohme, Mylan, Norgine, Ono Pharmaceutical, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Theravance Biopharma, Thermo Fisher Scientific, Tillots Pharma AG, Viatris, and Vifor Pharma, M. Watanabe Grant / Research support from: AbbVie, Alfresa Pharma, EA Pharma, Kissei, Kyorin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Takeda, and Zeria Pharmaceutical, Consultant of: AbbVie, Boehringer Ingelheim, EA Pharma, Eli Lilly Japan K.K., Gilead Sciences, Nippon, and Takeda, Speakers bureau of: EA Pharma, Eli Lilly Japan K.K., Gilead Sciences, Janssen, JIMRO, Kissei, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer Japan, Takeda, and Zeria Pharmaceutical, R. Panaccione Grant / Research support from: AbbVie, Ferring Pharmaceuticals, Janssen, Pfizer, and Takeda, Consultant of: Abbott, AbbVie, Alimentiv, Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmo Pharmaceuticals, Eisai, Elan Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Therapeutics, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda, Theravance Biopharma, and UCB Pharma, J. Jones: None Declared
APA, Harvard, Vancouver, ISO, and other styles
5

Berekoff, Beverley. "Conference 2016: From Drug Discovery to Health Outcomes: Population to Patient. An international symposium held jointly by CSPS and CC-CRS, May 31-June 3, 2016, Vancouver, BC, Canada." Journal of Pharmacy & Pharmaceutical Sciences 19, no. 3 (August 29, 2016): 1. http://dx.doi.org/10.18433/j36k7b.

Full text
Abstract:
Plenaries and Special Presentations:Carolyn Buser-Doepner, GSK: "New Trends in Pharma-Academia Collaborations for Drug Discovery"Chris Halyk, President, Janssen Inc.: "Are Innovative Medicines and our Life Sciences Industry at Risk in Canada?"Aaron Schimmer, Princess Margaret Cancer Centre: "New Therapeutic Strategies to Target the Mitochondria in Leukemia"Ivana Cecic, Genome BC: "Genomics in Canada: From Knowledge Generation to Patient Outcomes"Adam Rosebrock, University of Toronto: "Quantitative Mass-Spectrometry Metabolomics for Direct Biochemical Phenotyping"Fakhreddin Jamali, University of Alberta: CSPS Lifetime Achievement Award Lecture - "Pharmaceutical Research and Development, Lessons Learned"Conference Sessions:Special Session: Innovation and Management of Modern Pharmaceuticals1. Special Populations2. Nanomedicines Become Personal: Opportunities and Challenges3. Mucosal Drug Delivery4. Broaching the Fourth Hurdle: Getting Drugs on the Formulary5. Pharmacogenomics in the Clinic and Community6. Responsive Drug Delivery Systems7. Drug Targeting and Targeting Drugs8. Health Sustainability Evidence9. Integrating Pharmaceutical Sciences into a Pharm D Curriculum10. Analytical Innovation to Support Precision Medicine and Biologicals Development11. Protein and Peptide Delivery
APA, Harvard, Vancouver, ISO, and other styles
6

Soto, Stephany. "Intellectual property in the bio-sector research:." Revista Peruana de Biología 27, no. 1 (March 4, 2020): 103–6. http://dx.doi.org/10.15381/rpb.v27i1.17587.

Full text
Abstract:
Intellectual Property is a powerful legal and economic instrument. In our “knowledge economy”, patents are the preferred IP tool with special emphasis in the pharma – agro biotech industry. However, the growth of patents in the bio sector such as the pharma and agro fields, encounters many challenges. Life itself has not been defined yet. So, how can it be determined exactly when a living being, or a biological entity has been modified by itself or by human intervention, and thus address issues of patentability? Therefore, a researcher in the bio field cannot be alien to Intellectual Property, being the main actor in the revolution of the bio-pharma-agro sectors.
APA, Harvard, Vancouver, ISO, and other styles
7

Bazzanella, A. "Die Industrieplattform Mikroverfahrenstechnik– Eine deutsche Initiative zur Förderung der Mikrotechnik in Chemie, Pharma und Life Sciences." Chemie Ingenieur Technik 76, no. 5 (May 2004): 511–13. http://dx.doi.org/10.1002/cite.200403404.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sands, B. E., B. Feagan, T. H. Gibble, K. A. Traxler, N. Morris, X. Li, S. Schreiber, V. Jairath, A. Armuzzi, and J. Jones. "A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (March 1, 2023): 16–17. http://dx.doi.org/10.1093/jcag/gwac036.031.

Full text
Abstract:
Abstract Background The inflammatory bowel disease questionnaire (IBDQ) is a measure of health-related quality of life (QoL), with higher scores indicating greater QoL. In a prior phase 2 study (NCT02589665), mirikizumab, an anti-IL23p19 antibody, demonstrated efficacy and improvement in IBDQ scores in participants with moderately to severely active ulcerative colitis (UC). Purpose This analysis evaluated effect of mirikizumab (miri) vs placebo (PBO) on IBDQ scores in patients (pts) with moderately to severely active ulcerative colitis (UC) who had failed prior conventional or biologic therapy in a Phase 3, double-blind, 12-week (W) induction study (LUCENT-1) followed by a 40W maintenance study (LUCENT-2) for a total of 52W continuous therapy. Method Pts (N=1162) in LUCENT-1 were randomized 3:1 to receive 300mg miri or PBO intravenously once every four weeks (Q4W). 544 pts who achieved Modified Mayo Score Clinical Response to miri by W12 of induction were rerandomized 2:1 in LUCENT-2 to subcutaneous miri 200mg or PBO Q4W in maintenance period. Randomization was stratified by previous biologic therapy failure, baseline corticosteroid use, and region. LUCENT-1 stratification included baseline (BL) disease activity, and LUCENT-2 included LUCENT-1 clinical remission status. The least squares mean change from BL in IBDQ scores at W12 of induction and W40 of maintenance was determined using analysis of covariance models. BL was W0 of therapy and stratification factors and BL scores were used as covariates. The Minimal Clinically Important Difference (MCID) was defined as an improvement of ≥16 points in total IBDQ score (IBDQ response) and IBDQ remission as a total score ≥170 points. IBDQ response and remission were calculated using non-responder imputations. Treatments were compared using the common risk difference (risk diff). Result(s) Miri treatment resulted in significantly greater improvement from BL in IBDQ total and domain scores vs PBO at both W12 of induction and W40 of maintenance (52W treatment) (Table). The proportions of pts who achieved an IBDQ response was significantly greater for miri treated pts vs PBO at W12 (risk diff =17.1[95%CI:10.7, 23.5]) and W40 (29.5 [21.0, 37.9]). Significantly greater proportions of pts receiving miri achieved IBDQ remission at W12 (18.1 [11.8, 24.4]) and W40 (28.5 [20.1, 37.0]) vs PBO (all evaluations and timepoints: p<0.001). Image Conclusion(s) Pts reported significantly greater improvements in IBDQ scores at induction and maintenance with miri compared to PBO. Over 75% of pts achieved a clinically meaningful improvement in QoL, as measured by IBDQ response, at the end of the 52 weeks of miri treatment. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Eli Lilly and Company Disclosure of Interest B. Sands Consultant of: Abivax, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Calibr, Celltrion, ClostraBio, Eli Lilly and Company, Enthera, Evommune, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Kaleido Biosciences, Kallyope, MiroBio, Morphic Therapeutic, MRM Health, Pfizer, Progenity, Prometheus Therapeutics and Diagnostics, Protagonist Therapeutics, Q32 Bio, Surrozen, Takeda, Teva, TLL Pharmaceutical, USWM Enterprises, and Viela Bio, B. Feagan Shareholder of: Gossamer Bio, Consultant of: AbbVie, AdMIRx, AgomAb Therapeutics, Akebia Therapeutics, Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Avir Pharma, Azora Therapeutics, Boehringer Ingelheim, Boston Scientific, Celgene/Bristol Myers Squibb, Connect BioPharma, Cytoki Pharma, Disc Medicine, Ecor1 Capital, Eli Lilly and Company, Equillium, Everest Clinical Research, F. Hoffmann-La Roche, Ferring Pharmaceuticals, Galapagos NV, Galen/Atlantica, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Gossamer Bio, HotSpot Therapeutics, Imhotex, ImmuNext, InDex Pharmaceuticals, Intact Therapeutics, Janssen, Japan Tobacco, Kaleido Biosciences, Leadiant Biosciences, Millennium Pharmaceuticals, MiroBio, Morphic Therapeutics, Mylan, Novartis, OM Pharma, Origo Biopharma, Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Therapeutics and Diagnostics, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, Biopharma, Redx Pharma, Sandoz, Sanofi, Seres Therapeutics, Surrozen, Takeda, Teva, Thelium Therapeutics, Theravance Biopharma, TiGenix, Tillotts Pharma AG, UCB Pharma, VHsquared, Viatris, Ysios Capital, and Zealand Pharma, T. Gibble Employee of: Eli Lilly and Company, K. Traxler Employee of: Eli Lilly and Company, N. Morris Employee of: Eli Lilly and Company, X. Li Employee of: Eli Lilly and Company, S. Schreiber Grant / Research support from: personal fees and/or travel support from: AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly and Company, Dr. Falk Pharma, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos NV, Gilead Sciences, I-MAB Biopharma, Janssen, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Protagonist Therapeutics, Provention Bio, Roche, Sandoz/Hexal, Shire, Takeda, Theravance Biopharma, and UCB Pharma, V. Jairath Consultant of: AbbVie, Alimentiv, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Ferring Pharmaceuticals, Flagship Pioneering, Fresenius Kabi, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Pandion Therapeutics, Pendopharm, Pfizer, Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Shire, Takeda, Teva, Topivert, Ventyx Biosciences, and Vividion Therapeutics, A. Armuzzi Consultant of: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly and Company, Ferring Pharmaceuticals, Galapagos NV, Gilead Sciences, Janssen, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda, and TiGenix, J. Jones: None Declared
APA, Harvard, Vancouver, ISO, and other styles
9

Gossec, L., D. Aletaha, P. Sewerin, A. Zabotti, F. Van den Bosch, M. Efficace, F. Lavie, M. Zimmermann, M. Sharaf, and I. Mcinnes. "AB1082 EARLY CLINICAL RESPONSE AS A PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND TNFI-IR RECEIVING GUSELKUMAB (COSMOS)." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1761.1–1761. http://dx.doi.org/10.1136/annrheumdis-2023-eular.359.

Full text
Abstract:
BackgroundImprovement in health-related quality of life (HRQoL) is a key goal of psoriatic arthritis (PsA) therapy.[1,2]Here, we assess whether early clinical response predicts long-term improvement in HRQoL for patients (pts) with PsA and inadequate response to 1–2 tumour necrosis factor inhibitors (TNFi-IR).ObjectivesAssess the association between early clinical response across various PsA domains and HRQoL at Week (W)48, as well as identify baseline (BL) characteristics that could predict early response in guselkumab (GUS)-treated TNFi-IR PsA pts in the Phase 3b COSMOS trial.MethodsIn the randomized controlled COSMOS trial (NCT03796858),[3]adults with active PsA (swollen/tender joint counts [SJC/TJC] each ≥3) and TNFi-IR were randomized 2:1 to receive subcutaneous injections of either GUS 100 mg (at W0, W4, then every 8 weeks through W44) or placebo (at W0, W4, W12, W20, followed by GUS at W16 [early escape] or at W24 [planned], W28, W36, W44). Only pts randomized to GUS were included in this analysis. Long-term improvements in HRQoL were defined as changes from BL to W48 in 36-item short-form survey (SF-36) physical and mental component summary (PCS and MCS) and Dermatology Life Quality Index (DLQI) scores. Early clinical response was defined as achievement of the following criteria at W4 or W8: American College of Rheumatology (ACR)20, pt pain on a visual analogue scale (VAS) ≤15,SJC ≤1, skin VAS ≤20, and health assessment questionnaire – disability index.(HAQ-DI) ≤0.5. In addition, Psoriasis Area and Severity Index (PASI) ≤1 was considered at W16 – the earliest PASI assessment. Analyses were restricted to pts not meeting the respective early response criteria at BL. Long-term HRQoL improvements were compared between pts achieving vs not achieving early response criteria by means of Student’s.t-test and by multivariate linear regression models adjusting for demographic and BL pt disease characteristics. Results from the multivariate linear regression analyses are presented here. Demographic and BL pt disease characteristics predicting early clinical response were investigated using multivariate logistic regression.ResultsOverall, 189 pts were randomized to GUS, with a mean age of 49.1 years, and 45.5% were male. Among pts not meeting the respective early response criteria at BL, GUS led to.2.7–19.0% and 4.3–38.4% of pts achieving one of the clinical responses of interest as early as W4 and W8, respectively. SF-36 PCS improvement from BL to W48 was significantly associated with ACR20 response, SJC ≤1 and HAQ-DI ≤0.5 achievement at W4 as well as at W8. There were no significant findings for SF-36 MCS. DLQI improvement from BL to W48 was significantly associated with ACR20 and skin VAS ≤20 at W8 (Figure 1). Improvements in SF-36 PCS, SF-36 MCS and DLQI at W48 were all significantly associated with achievement of PASI ≤1 at W16. Multivariate logistic regression identified significant (P<0.05) associations between males and early clinical response at W8 (ACR20: odds ratio [OR]=1.98; HAQ-DI ≤0.5: OR=3.71), BL SJC and.SJC ≤1 at W8 (OR=0.84), BL HAQ-DI and HAQ-DI ≤0.5 at W8 (OR=0.23), and BL skin VAS and skin VAS ≤20 at W8 (OR=0.98).ConclusionFor pts receiving GUS, ACR20 response at W4 and W8 was positively associated with SF-36 PCS improvement from BL to W48, and also at W8 with DLQI improvement from BL to W48. Therefore, early clinical response is relevant for HRQoL improvements over time. These results may help in shared decision-making processes.References[1]Gossec Let al Ann Rheum Dis2020;79:700–12[2]Coates LCet al. Nat Rev Rheumatol2022;18:465–79[3]Coates LCet al Ann Rheum Dis2022;81:359–69Acknowledgements:NIL.Disclosure of InterestsLaure Gossec Consultant of: AbbVie, Amgen, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB, Grant/research support from: Sandoz, UCB, Daniel Aletaha Speakers bureau: Abbvie, Gilead, Galapagos, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Consultant of: Abbvie, Gilead, Galapagos, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Grant/research support from: Abbvie, Gilead, Galapagos, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Philipp Sewerin Speakers bureau: AXIOM Health, Amgen, AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Chugai Pharma Marketing Ltd./ Chugai Europe, Deutscher Psoriasis-Bund, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly/ Lilly Europe/ Lilly Global, medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein-Ruhr, Sanofi-Genzyme, Spirit Medical Communications, Swedish Orphan Biovitrum, UCB Pharma, Consultant of: AXIOM Health, Amgen, AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Chugai Pharma Marketing Ltd./ Chugai Europe, Deutscher Psoriasis-Bund, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly/ Lilly Europe/ Lilly Global, medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein-Ruhr, Sanofi-Genzyme, Spirit Medical Communications, Swedish Orphan Biovitrum, UCB Pharma, Grant/research support from: AXIOM Health, Amgen, AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Chugai Pharma Marketing Ltd./ Chugai Europe, Deutscher Psoriasis-Bund, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly/ Lilly Europe/ Lilly Global, medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein-Ruhr, Sanofi-Genzyme, Spirit Medical Communications, Swedish Orphan Biovitrum, UCB Pharma, Alen Zabotti Speakers bureau: AbbVie, Novartis, Janssen, Lilly, UCB, Amgen, Paid instructor for: AbbVie, Novartis, UCB, Filip van den Bosch Consultant of: AbbVie, Amgen, Eli Lilly, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB, Michela Efficace Shareholder of: Janssen Pharmaceutical Companies of Johnson and Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson and Johnson, Frederic Lavie Shareholder of: Johnson & Johnson, Abbvie, Employee of: The Janssen Pharmaceutical Companies of Johnson & Johnson, Miriam Zimmermann Employee of: Janssen Pharmaceutical Companies of Johnson and Johnson, Mohamed Sharaf Employee of: Janssen Pharmaceutical Companies of Johnson and Johnson, Iain McInnes Speakers bureau: Abbvie, Consultant of: Amgen Abbvie, Astra Zeneca, GSK, Lilly, Sanofi, Evelo, Compugen, Cabaletta, UCB, Novartis, BMS, Causeway Therapeutics, Gilead, Moonlake, Pfizer, Janssen, Grant/research support from: Amgen, AstraZeneca, BMS, Lilly Novartis, Janssen, GSK, UCB, Pfizer.
APA, Harvard, Vancouver, ISO, and other styles
10

Walker, D., T. Takeuchi, B. Bartok, S. Rao, I. H. Lee, R. Besuyen, J. E. Gottenberg, and M. C. Genovese. "FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 652–53. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2901.

Full text
Abstract:
Background:EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1However, patients consider reduction in pain and fatigue, along with maintenance of physical function, and improvement in health-related quality of life (HRQoL) important areas for improvement with RA treatment.2In the FINCH 2 study, filgotinib (FIL)—a potent, selective, oral small molecule Janus kinase 1 inhibitor—in combination with conventional synthetic (cs)DMARD therapy significantly improved the signs and symptoms of rheumatoid arthritis (RA) in patients with an inadequate response to a biologic (b)DMARD compared with placebo (PBO).3In addition, patients experienced significant improvements in HAQ-DI at week (W)12 and W24 with FIL 100 mg (p <0.001, p = 0.003) or 200 mg (p <0.001 for both) compared with PBO.3Objectives:To evaluate the rate and magnitude of change in patient-reported outcomes (PROs) from FINCH 2 assessing pain, HRQoL, and fatigue.Methods:Patients in this double-blind, randomised study (NCT02873936) received FIL 200 mg, FIL 100 mg, or PBO while continuing csDMARD therapy. PROs were collected prospectively on day 1 and at the W2, W4, W8, W12, W14, W16, W20, and W24 visits for assessment of pain (VAS pain scale) and on day 1 and at W4, W12, and W24 for assessment of fatigue (FACIT-Fatigue) and HRQoL (SF-36). Changes from baseline for each PRO at each time point up to W24 were analysed longitudinally using a mixed-effects model for repeated measures. P values for the difference between each FIL arm and PBO at each time point were calculated.Results:Among the 448 patients randomised and treated (FIL 200 mg, n = 147; FIL 100 mg, n = 153; PBO, n = 148) 381 (85.0%) completed the study. Baseline mean (SD) VAS pain scale was 67 (21.0), SF-36 physical component summary (PCS) was 31.1 (7.89), SF-36 mental component summary (MCS) was 44.3 (11.6), and FACIT-Fatigue score was 24.4 (11.6); baseline values did not vary between treatment groups. Significantly greater improvements in VAS pain scores began at W2 and were maintained through W24 for patients who received either dose of FIL vs PBO (Fig 1A). FIL also significantly improved patients’ fatigue at W4, W12, and W24 compared with PBO for those receiving 200 mg doses, and at W4 and W12 for those receiving 100 mg doses (Fig 1B). HRQoL related to physical functioning (SF-36 PCS) was significantly enhanced at W4, W12, and W24 with both doses of FIL as compared with PBO (Fig 2A). Improvements to mental-health-related QoL (SF-36 MCS) were reported for FIL as early as W4 and maintained through W24, with statistically significant improvements at W4 and W12 for FIL 200 mg vs PBO (Fig 2B).Conclusion:In a patient population with refractory disease that had inadequate response to prior bDMARDs and had significant disease at baseline, FIL treatment—coadministered with csDMARD therapy—was able to provide rapid and sustained improvements in key measures of pain, HRQoL, and fatigue as reported by patients.References:[1]Smolen, et al.Ann Rheum Dis. 2017;76:960–77.[2]Fautrel, et al.Rheumatol Int.2018;38:935–47.[3]Genovese, et al.JAMA. 2019;322(4):315–25.Disclosure of Interests:David Walker Grant/research support from: Gilead, Consultant of: Gilead, Lilly, Pfizer, Roche, Speakers bureau: Lilly, Pfizer, Roche, Tsutomu Takeuchi Grant/research support from: AbbVie, Asahikasei Pharma Corp., Astellas Pharma, Inc., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mitsubishi-Tanabe Pharma Corp., Nipponkayaku Co. Ltd., Shionogi & Co., Ltd., Takeda Pharmaceutical Co., Ltd., UCB Japan, Consultant of: Astellas Pharma, Inc., Chugai Pharmaceutical Co, Ltd., Eli Lilly Japan,, Speakers bureau: Abbvie, AYUMI Pharmaceutical Corp., Bristol-Myers Squibb, Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan, Gilead Sciences, Inc., Mitsubishi-Tanabe Pharma Corp., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi K.K., Dainippon Sumitomo Co., Ltd, Beatrix Bartok Shareholder of: Gilead Sciences Inc., Employee of: Gilead Sciences Inc., Shangbang Rao Shareholder of: Gilead Sciences Inc., Employee of: Gilead Sciences Inc., I-Heng Lee Shareholder of: Gilead Sciences Inc., Employee of: Gilead Sciences Inc., Robin Besuyen Shareholder of: Galapagos, Employee of: Galapagos, Jacques-Eric Gottenberg Grant/research support from: BMS, Pfizer, Consultant of: BMS, Sanofi-Genzyme, UCB, Speakers bureau: Abbvie, Eli Lilly and Co., Roche, Sanofi-Genzyme, UCB, Mark C. Genovese Grant/research support from: Abbvie, Eli Lilly and Company, EMD Merck Serono, Galapagos, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, Pfizer Inc., RPharm, Sanofi Genzyme, Consultant of: Abbvie, Eli Lilly and Company, EMD Merck Serono, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, RPharm, Sanofi Genzyme
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "PHARMA] Life Sciences"

1

Salem, Hanaa A. "Design and evaluation of a hepatitis B immunization program for pharmacy students." Scholarly Commons, 1992. https://scholarlycommons.pacific.edu/uop_etds/2226.

Full text
Abstract:
The objectives of this study are: (1) To compare the effectiveness of two dosing schedules of hepatitis B vaccine in achieving compliance within the vaccines; (2) To determine the immunization requirements in U.S. pharmacy schools both at admission and before the students begin clinical clerkships; and, (3) To design an immunization program for pharmacy students at the University of the Pacific in an attempt to enhance compliance.
APA, Harvard, Vancouver, ISO, and other styles
2

McCreary, Andrew C. "Aspects of tic like behaviour and serotonergic control." Thesis, Aston University, 1995. http://publications.aston.ac.uk/11052/.

Full text
Abstract:
Tic-like movements in rodents bear close similarities to those observed in humans both pharmacologically and morphologically. Pharmacologically, tics are modulated by serotonergic and dopaminergic systems and abnormalities of these systems have been reported in Tourette's Syndrome (TS). Therefore, serotonergic and dopaminergic modulation of tics induced by a thyrotrophin-releasing hormone (TRH) analogue were studied as possible models for TS. The TRH analogue MK771 induced a variety of tic like movements in mice; blinking fore-paw-licking and fore-paw-tremor were quantified and serotonergic and dopaminergic modulation was investigated. The selective dopamine D1 receptor antagonists SCH23390 and SCH39166 and dopamine D2 antagonists raclopride and sulpiride had no effect on MK771 induced blinking. The D1 antagonists attenuated fore-paw-tremor and -licking while the D2 antagonists were generally without effect on these behaviours. Ketanserin (5-HT2A/ alpha-1 antagonist) and ritanserin (5-HT2A/2C antagonist) were able to attenuate MK771-induced blinking and ketanserin, mianserin (5-HT2A/2C antagonist) and prazosin (alpha-1 adrenoceptor antagonist) were able to attenuate MK771-induced fore-paw-tremor and -licking. The 5-HT2C/2B antagonist SB200646A was without effect on blinking and fore-paw-licking but dose-dependently potentiated fore-paw-tremor. The 5-HT1A agonists 8-OH DPAT and buspirone attenuated blinking at the lower doses tested but were ineffective at the higher doses; the converse was found for fore-paw-licking and -tremor behaviours.
APA, Harvard, Vancouver, ISO, and other styles
3

Calhoun, McKenzie L. "The Journey to Team Based Healthcare: A Day in the Life." Digital Commons @ East Tennessee State University, 2010. https://dc.etsu.edu/etsu-works/6878.

Full text
Abstract:
To offer an insight into the themes which will be explored at the Masterclass, in this short video Dr. McKenzie Calhoun and colleagues at the ETSU Family Physicians in Kingsport, Tennessee discuss how a model of interprofessional collaboration is typically applied and put into practice in the care of patients at the center. They highlight the importance and value of a team-based approach in enhancing the provision of primary healthcare.
APA, Harvard, Vancouver, ISO, and other styles
4

Thakkar, Jay. "Biochemical Evaluation of Lignin-like Molecules." VCU Scholars Compass, 2011. http://scholarscompass.vcu.edu/etd/199.

Full text
Abstract:
Current anticoagulants carry a serious risk of bleeding complications. In addition, narrow therapeutic index, drug interactions, immunological reactions, toxicity and high cost to benefit ratio limits the effective use of these drugs in patients with thrombotic conditions.Heparin is the most widely used anticoagulant. We hypothesized that one of the major drawback of heparins, its non-specific interaction with the plasma proteins arises as a result of negative charges. To reduce these non-specific interactions, our laboratory designed sulfated low molecular weight lignin (LMWL) like biomacromolecules, which were found to be direct inhibitors of thrombin and factor Xa, acting through a unique exosite-2 mediated process. To elucidate the structural basis of this mechanism, we studied unsulfated and size fractionated LMWLs. Detailed enzyme inhibition studies with sulfated and unsulfated LMWLs of ferulic and caffeic acid oligomers revealed that sulfation was not absolutely critical for dual inhibition property and smaller oligomers can yield a potent anticoagulant. Mechanistically, unsulfated LMWLs retained exosite-2 mediated inhibition mechanism. A major advantage expected of the unsulfated LMWLs is the possibility that orally bioavailable anticoagulants may become possible.To identify target specific structures within the heterogeneous population of sulfated LMWLs, we prepared sulfated β-O-4-linked oligomer using chemical synthesis. Enzyme inhibition studies revealed that the sulfated β-O-4 LMWL were highly selective direct inhibitors of thrombin. These results show for the first time that specific structural features on LMWL scaffold dictate inhibition specificity. Studies in plasma and blood display highly promising anticoagulant profile for further studies in animals. To further study the LMWL scaffold as macromolecular mimetic of heparin; we investigated their effect in preventing cellular infection by herpes simplex virus-1 (HSV-1). Based on previous findings on sulfated lignins a size-dependent study on unsulfated LMWLs was done. The unsulfated lignins were found to not only inhibit HSV-1 entry into mammalian cells, but were more potent than sulfated lignins. Interestingly, shorter chains were found to be as active as the longer ones, suggesting that structural features, in addition to carboxylate groups, may be important. It can be expected that unsulfated lignins also antagonize the entry of other enveloped viruses, like HIV-1 and HCV that utilize heparan sulfate to gain entry into cells. The results further present major opportunities for developing lignin-based antiviral formulations for topical use.
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, Fang. "HARNESSING TRANSTHYRETIN TO ENHANCE THE IN VIVO HALF-LIFE OF HUMAN INTERLEUKIN-2 (IL-2)." Scholarly Commons, 2021. https://scholarlycommons.pacific.edu/uop_etds/3764.

Full text
Abstract:
Protein therapeutics are available as cytokines, clotting factors, enzymes, hormones, growth factors, antibodies et al. They have been shown to be effective in treating a variety of important human diseases. Since human insulin was approved as the first recombinant protein therapeutic, this field has experienced rapid growth. One of the biggest challenges for protein therapeutics in clinical application is their short half-life. Except for monoclonal antibodies, which have serum half-life for weeks, most of the protein therapeutics have half-lives ranging from minutes to hours. Kidney filtration, proteasome degradation and liver metabolism are the main factors that attribute to their short half-lives. The short half-life of protein therapeutics requires a higher dose or frequent application to maintain therapeutic concentration over a certain period. However, higher dose is easy to cause large plasma concentration fluctuation, which is easy to cause side effects. Most of protein therapeutics are not orally bioavailable. Frequent application will increase the burden of patients, affect their life quality, and reduce patient compliance. Thus, it is important to generate long-lasting therapeutics with improved pharmacokinetic properties. The current half-life extension approaches for protein therapeutics include PEGylation, albumin fusion or binding and fusion to an immunoglobulin Fc region. Their primary aim is to increase the size of biotherapeutics or to implement recycling by the neonatal Fc receptor (FcRn). However, the half-life extension by PEGylation, albumin fusion or Fc fusion is at the cost of binding affinity reduction. And the increase of size has limited their application in the field of anticancer agents where tumor penetration is required. Noncovalent albumin binding using albumin binding ligands such as fatty acids could maintain the small size and binding affinity. However, it would increase hydrophobicity, therefore is not suitable for protein therapeutics with low solubility. Here, we present a new approach for half-life extension for biotherapeutics. Human interleukin 2 (IL-2), a low solubility cytokine, was used as a model protein. By conjugating IL-2 with a hydrophilic small molecule that binds reversibly to the serum protein transthyretin, we enhanced its circulation half-life in rodents while maintained its in vitro bioactivity. To the best of our knowledge, this is the first demonstration of a successful approach that harnesses a small molecule in extending the circulation half-life of a protein while at the same time maintains the small size and hydrophilicity.
APA, Harvard, Vancouver, ISO, and other styles
6

Evers, Frank Richard. "Development of a liquid chromatography ion trap mass spectrometer method for clinical drugs of abuse testing with automated on-line extraction using turbulent flow chromatography." Thesis, University of Portsmouth, 2014. https://researchportal.port.ac.uk/portal/en/theses/development-of-a-liquid-chromatography-ion-trap-mass-spectrometer-method-for-clinical-drugs-of-abuse-testing-with-automated-online-extraction-using-turbulent-flow-chromatography(c047da7d-eb8a-41d0-ad1c-830deca531dc).html.

Full text
Abstract:
Aims The method for the confirmation of drugs of abuse for addiction testing within King’s College Hospital prior to 2008 was a labour intensive thin layer chromatography method. To replace this with a faster method more suited to future requirements, the laboratory bought a liquid chromatography system with ion trap mass spectrometric detection. The development of the routine analytical method and the implementation of this method within the laboratory using on-line solid phase extraction and Turboflow® sample preparation will allow the laboratory to operate successfully in the field of clinical drugs of abuse testing in the future. Method Analyses are performed on an ion trap mass spectrometer with an electrospray ion source following reversed phase liquid chromatography, initially using on-line solid phase extraction with a Jasco XLC® series autosampler and pump and later a Thermo Turboflow® on-line extraction method with a CTC Combi-Pal® autosampler and Agilent 1100 series liquid chromatography system. Elution of drugs and metabolites is performed with a multi-step gradient of ammonium formate buffer and acetonitrile, followed by regeneration of the extraction and analytical columns to starting conditions. Detection is achieved with a Thermo LCQ Fleet ion trap mass spectrometer with a combination of full spectrum survey scans, dedicated product ion scans, neutral loss scans and data dependent product ion scans in two analysis segments. Total run time is only 20 minutes, allowing a throughput of around 65 samples per day. Results The methods include the novel combination of the elimination of any hydrolysis step, on-line SPE or Turboflow extraction, detection of multiple drug groups, full spectrum analysis and library matching, the use of data dependent scans and ion trap mass spectrometry using MS3 and neutral loss scans. The methods developed were validated using a departmental method validation protocol and accepted for routine use. Simultaneous detection of over fifty analytes has been found possible in a range of clinically relevant drug groups, including opiates, amphetamines, methadone, propoxyphene, cocaine, ketamine and their metabolites. The use of neutral loss scans and product ion scans of phase 2 drug metabolites permits the addition of previously unidentified drugs and metabolites to the method, allowing the laboratory’s services to develop in line with requirements of the service. Quality is maintained through the use of standard operating procedures, staff training, quality control samples and external quality assessment. Conclusion Drugs of abuse testing is key for treatment and monitoring of drug addiction. The introduction of modern mass spectrometry techniques has reduced the turnaround time of routine analysis for a range of drugs and metabolites and increased the range of drugs that can be analysed. The methods introduced have revolutionised testing at King’s College Hospital and produced a method which is capable of evolving with the needs of the service to keep abreast of future requirements of the service.
APA, Harvard, Vancouver, ISO, and other styles
7

Harpe, Spencer E. "Assessing health state preferences and the decision to medicate in overactive bladder." Columbus, Ohio : Ohio State University, 2004. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1078937770.

Full text
Abstract:
Thesis (Ph. D.)--Ohio State University, 2004.
Title from first page of PDF file. Document formatted into pages; contains xiii, 154 p.; also includes graphics (some col.). Includes abstract and vita. Advisor: Sheryl L. Szeinbach, College of Pharamcy. Includes bibliographical references (p. 139-154).
APA, Harvard, Vancouver, ISO, and other styles
8

Penchala, Sravan C. "Characterization of AG10, a potent stabilizer of transthyretin, and its application in enhancing in vivo half-life of therapeutic peptides." Scholarly Commons, 2016. https://scholarlycommons.pacific.edu/uop_etds/130.

Full text
Abstract:
The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, underlies a large number of human degenerative diseases. Cardiac amyloidoses, which are most commonly caused by aggregation of Immunoglobulin (Ig) light chains or transthyretin (TTR) in the cardiac interstitium and conducting system, represent an important and often underdiagnosed cause of heart failure. Two types of TTR-associated amyloid cardiomyopathies are clinically important. The Val122Ile (V122I) mutation, which alters the kinetic stability of TTR and affects 3% to 4% of African Americans, can lead to development of familial amyloid cardiomyopathy. In addition, aggregation of WT TTR in individuals older than age 65 years causes senile systemic amyloidosis. TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead to arrhythmias, biventricular heart failure, and death. As no Food and Drug Administration-approved drugs are currently available for treatment of these diseases, the development of therapeutic agents that prevent TTR-mediated cardiotoxicity is desired. Here, we report the characterization of AG10 , a potent and selective kinetic stabilizer of TTR. AG10 prevents dissociation of V122I-TTR in serum samples obtained from patients with familial amyloid cardiomyopathy. In contrast to other TTR stabilizers currently in clinical trials, AG10 stabilizes V122I- and WT-TTR equally well and also exceeds their efficacy to stabilize WT and mutant TTR in whole serum. Crystallographic studies of AG10 bound to V122I-TTR give valuable insights into how AG10 achieves such effective kinetic stabilization of TTR, which will also aid in designing better TTR stabilizers. The oral bioavailability of AG10 , combined with additional desirable drug-like features, makes it a very promising candidate to treat TTR amyloid cardiomyopathy. The second part of the thesis discusses harnessing TTR as a platform to enhance in vivo half-life of therapeutic peptides. The tremendous therapeutic potential of peptides has not yet been realized, mainly owing to their short in vivo half-life. Although conjugation to macromolecules has been a mainstay approach for enhancing protein half-life, the steric hindrance of macromolecules often harms the binding of peptides to target receptors, compromising the in vivo efficacy. Here we report a new strategy for enhancing the in vivo half-life of a model peptide Gonadotropin Releasing Hormone (GnRH) and its analog GnRH-A without compromising their potency. Apart from GnRH, we have used other peptides to study their proteolytic stability in vitro . Our approach involves endowing peptides with a small molecule that binds reversibly to the serum protein transthyretin. Although there are a few molecules that bind albumin reversibly, we are unaware of designed small molecules that reversibly bind other serum proteins and are used for half-life extension in vivo . We show here that our strategy was effective in enhancing the half-life of an agonist for GnRH receptor while maintaining its binding affinity, which was translated into superior in vivo efficacy.
APA, Harvard, Vancouver, ISO, and other styles
9

Jampala, Raghavendra. "Synthesis of AG10 analogs and optimization of TTR ligands for Half-life enhancement (TLHE) of Peptides." Scholarly Commons, 2017. https://scholarlycommons.pacific.edu/uop_etds/2975.

Full text
Abstract:
The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, underlies a large number of human degenerative diseases. Cardiac amyloidosis, which is most commonly, caused by aggregation of Immunoglobulin (Ig) light chains or transthyretin (TTR) in the cardiac muscle, represent an important and often underdiagnosed cause of heart failure. TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead to arrhythmias, biventricular heart failure, and death. As no Food and Drug Administration-approved drugs are currently available for treatment of these diseases, the development of therapeutic agents that prevent TTR-mediated cardiotoxicity is desired. AG10 is a potent and selective kinetic stabilizer of TTR. AG10 prevents dissociation of TTR in serum samples obtained from patients with amyloid cardiomyopathy. The oral bioavailability and selectivity of AG10, makes it a very promising candidate to treat TTR amyloid cardiomyopathy. Understanding the reason behind the potency of AG10 would be beneficial for designing stabilizers for other amyloid diseases. This would be possible by designing and synthesizing structural analogues of AG10. Here we report the synthesis, characterization and analysis of AG10 analogs and the comparison of the in vitro activities of the synthesized analogs. The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short In vivo half-life resulting from inactivation by serum proteases and rapid elimination by kidneys. Extending the In vivo half-life of peptides is clearly desirable in order for their therapeutic potential to be realized, without the need for high doses and/or frequent administration. Covalent conjugation of peptides to macromolecules (e.g. polyethylene glycol or serum proteins such albumin) has been the mainstay approach for enhancing the In vivo half-life of peptides. However, the steric hindrance and immunogenicity of these large macromolecules often compromises the In vivo efficacy of the peptides. Recently, our laboratory established the first successful reversible method of extending the half-life of peptides using serum protein TTR. The approach involved the use of a TTR Ligand for Half-life Extension (TLHE-1) which binds to TTR with high specificity and affinity. We have shown that our technology extends the half-life of multiple peptides without seriously affecting their activity. Our main objective here is to modify the structure of TLHE1 using linkers with different length and composition to optimize its affinity and selectivity for TTR in human serum.
APA, Harvard, Vancouver, ISO, and other styles
10

Luo, Xiao Luo. "Development of Lipid-like Nanoparticles for mRNA Delivery." The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1511778914988389.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "PHARMA] Life Sciences"

1

Berufs- und Karriere-Planer Life Sciences 2007-2008: Fu r Studenten und Hochschulabsolventen ; Special Pharma-Industrie. 5th ed. Wiesbaden: Gabler Verlag / GWV Fachverlage, Wiesbaden, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dawson, Delilah S. Phasma. New York: Random House Audio, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pfeil, W. Protein Stability and Folding: A Collection of Thermodynamic Data. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pfeil, Wolfgang. Protein Stability and Folding: Supplement 1 A Collection of Thermodynamic Data. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ben-Naim, Arieh. Cooperativity and Regulation in Biochemical Processes. Boston, MA: Springer US, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Johns, Timothy. Functionality of Food Phytochemicals. Boston, MA: Springer US, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Romeo, John T. Phytochemicals in Human Health Protection, Nutrition, and Plant Defense. Boston, MA: Springer US, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Quality assurance: Problem solving and training strategies for success in the pharmaceutical and life science industries. Oxford: Woodhead Publishing, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mike, Reading, and Hourston Douglas J, eds. Modulated temperature differential scanning calorimetry: Theoretical and practical applications in polymer characterisation. Dordrecht: Springer, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

service), SpringerLink (Online, ed. Herbal Drugs and Fingerprints: Evidence Based Herbal Drugs. India: Springer India, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "PHARMA] Life Sciences"

1

Moorman, Mike, Namita Powers, Joe Stevens, and Rohan Agni. "The future of KAM in life sciences." In Key Account Management Excellence in Pharma & Medtech, 185–200. London: Routledge, 2022. http://dx.doi.org/10.4324/9781003226512-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schweizer, Lars, and Theodor Dingermann. "Introduction: Trends and Developments in the Pharmaceutical and Life Sciences Industry." In Advances in Pharma Business Management and Research, 1–5. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-35918-8_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schweizer, Lars, and Theodor Dingermann. "Correction to: Introduction: Trends and Developments in the Pharmaceutical and Life Sciences Industry." In Advances in Pharma Business Management and Research, C1. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-35918-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moorman, Mike, and Namita Powers. "Executive alignment and engagement: It's make or break for life sciences KAM programs." In Key Account Management Excellence in Pharma & Medtech, 67–79. London: Routledge, 2022. http://dx.doi.org/10.4324/9781003226512-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Eichner, Wolfram, and Marietta Miemietz. "Pharma-/Life-Science-Investments." In Life Science Venturing, 21–38. Wiesbaden: Springer Fachmedien Wiesbaden, 2016. http://dx.doi.org/10.1007/978-3-658-06382-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Blankenagel, Michael, Jung Kyu Canci, and Philipp Mekler. "Value Creation, Valuation and Business Models in the Pharmaceutical Sector." In Quantitative Models in Life Science Business, 3–16. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11814-2_1.

Full text
Abstract:
AbstractThe chapter describes value creation and valuation under structural uncertainty in the healthcare and pharma industries. These risks and uncertainties can significantly influence organizational performance, value creation and long-term sustainability. The discussion continues by comparing traditional valuation concepts used in finance with the requirements posed by the current situation of healthcare business. In particular, patent valuation is a critical business issue, and the value of pharma patents and licensing deals has risen markedly in recent years. Existing evaluation approaches do not consider a patent’s life cycle, an important and unique characteristic of pharma and biotech patents. For this reason, the inherent uncertainty in a patent’s value is modelled as a stochastic process.
APA, Harvard, Vancouver, ISO, and other styles
7

Mekler, Philipp, and Jingshu Sun. "Pharma Tender Processes: Modeling Auction Outcomes." In Quantitative Models in Life Science Business, 51–71. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11814-2_4.

Full text
Abstract:
AbstractThis chapter summarizes the overall tendering and contracting process in the pharmaceutical industry by providing an overview of the first-sealed price auction theory, auction rules, and drug pricing mechanism of different countries. Comparing procurement systems across Asia, Africa, Europe, and Latin America, the review casts light on various pharmaceutical bidding systems across the world and their impact on drug prices. Then, this review focuses on the empirical estimation of first-price auction models. In terms of model specification, we compare the two most commonly used empirical methods for bidding price estimation: structural models and reduced form approaches to test the auction theory. Maximum likelihood estimation is the most frequently used method for structural estimation in literature and selection bias correction is widely adopted using reduced form models. In addition to parametric model construction, we also provide an extensive introduction of non-parametric testing methodologies, including non-parametric estimation and quantile-based estimation to reduce the computation complexity and further illustrate how auction theory could be validated by real-world applications. Additional thoughts and adjustments on non-parametric testing are brought up based on a real-world tendering use case from a large multi-national pharmaceutical company.
APA, Harvard, Vancouver, ISO, and other styles
8

von Bohlen, Friedrich. "Life Science Informatik: Schlüssel für Innovation und nachhaltiges Wachstum in der Pharmabranche." In Strategien für das Pharma-Management, 55–64. Wiesbaden: Gabler Verlag, 2003. http://dx.doi.org/10.1007/978-3-322-87010-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Iazzolino, Gianpaolo, and Rita Bozzo. "Partnership Models for R &D in the Pharmaceutical Industry." In Quantitative Models in Life Science Business, 29–48. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11814-2_3.

Full text
Abstract:
AbstractOver the last decades the complexity of R &D processes in the pharmaceutical industry have resulted in a decline in the efficiency of those processes. Despite financial resources used in R &D have increased over time the number of drugs developed has remained almost constant. The phenomenon is known as “Eroom’s Law”. In order to start growing R &D efficiency again, the business models of companies were reviewed by mainly implementing open innovation models that can simplify and shorten the drug development process. Pharmaceutical companies are increasingly outsourcing activities from the external environment. The R &D tasks that firms choose to outsource include a wide spectrum of activities from basic research to late-stage development: genetic engineering, target validation, assay development, hit exploration and lead optimization (hit candidates-as-a-service), safety and efficacy tests in animal models, and clinical trials involving humans. Terms such as crowdsourcing, innovation centers, R &D collaboration, and open source are becoming more and more common in the sector. Almost all the Big Pharma are striving to create collaborative networks that might allow them to be more efficient. Pharmaceutical companies are called upon to make a “make or buy” decision to determine whether it is more convenient to outsource these activities rather than exploiting internal resources for generating innovation. In a global context in which the stochastic view has become more suitable for interpreting phenomena the aim of this kind of decision is mainly related to decrease uncertainty. The aim of the chapter is to explore this topic by also providing data and examples.
APA, Harvard, Vancouver, ISO, and other styles
10

Susiyarti and M. P. Mahardika. "Prescription off-label medicine for children at Saras Sehat Pharmacy in Tegal city." In Improving Health for Better Future Life: Strengthening from Basic Science to Clinical Research, 190–96. London: CRC Press, 2023. http://dx.doi.org/10.1201/9781032693408-32.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "PHARMA] Life Sciences"

1

Bhutada, Sunil, Saran Sri Dath Uppala, SriGeethika Nagavajyula, and Tarun Pottigari. "C2-PILS: A Chatbot using Chat-GPT for Pharma Industry and Life Sciences." In 2023 International Conference on Advanced Computing Technologies and Applications (ICACTA). IEEE, 2023. http://dx.doi.org/10.1109/icacta58201.2023.10392641.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yu, Manyou, Irene Gouvinhas, Paula Oliveira, and Ana Barros. "Pomegranate leaf, as a valuable by-product in food-pharma and nutraceutical industriesf Panama disease." In 1st International PhD Student’s Conference at the University of Life Sciences in Lublin, Poland: ENVIRONMENT – PLANT – ANIMAL – PRODUCT. Publishing House of The University of Life Sciences in Lublin, 2022. http://dx.doi.org/10.24326/icdsupl1.t043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yardi, Yardi, and Nelly Suryani. "The Perception of Fourth Year Pharmacy Student of UIN Syarif Hidayatullah Jakarta Towards the Pharmacy Profession." In 1st International Integrative Conference on Health, Life and Social Sciences (ICHLaS 2017). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/ichlas-17.2017.45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Du, Jiajun, and Lu Wei. "Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma." In Advanced Chemical Microscopy for Life Science and Translational Medicine 2021, edited by Garth J. Simpson, Ji-Xin Cheng, and Wei Min. SPIE, 2021. http://dx.doi.org/10.1117/12.2576833.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Suryani, Nelly, and Yardi Yardi. "A Study to Investigate the Perception of First Year Pharmacy Student of UIN Syarif Hidayatullah Jakarta Towards the Pharmacy Profession." In 1st International Integrative Conference on Health, Life and Social Sciences (ICHLaS 2017). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/ichlas-17.2017.49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ievtushenko, Olena, Irina Zhirova, and Irina Spichak. "Research of the Main Components of Risk Management in Pharmacy." In Proceedings of the 1st International Symposium Innovations in Life Sciences (ISILS 2019). Paris, France: Atlantis Press, 2019. http://dx.doi.org/10.2991/isils-19.2019.30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Matahari, Ratu, Wahyuni Arumsari, and Kartika Setyaningsih Sunardi. "What Elderly Needs to Improve Their Quality of Life? A Qualitative Study." In Proceedings of the 2019 Ahmad Dahlan International Conference Series on Pharmacy and Health Science (ADICS-PHS 2019). Paris, France: Atlantis Press, 2019. http://dx.doi.org/10.2991/adics-phs-19.2019.15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Baroroh, Faridah, and Andriana Sari. "Correlation between the Characteristics and Quality of Life of Hypertensive Outpatients at a Private Hospital in Yogyakarta." In Proceedings of the 2019 Ahmad Dahlan International Conference Series on Pharmacy and Health Science (ADICS-PHS 2019). Paris, France: Atlantis Press, 2019. http://dx.doi.org/10.2991/adics-phs-19.2019.30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Badriyya, Elsa, Afifatul Achyar, and Syamsurizal. "Primer Design of SNP rs4506565 Transcription Factor 7 like 2 (TCF7L2) Gene to Detect Type-2 Diabetes Mellitus." In 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021). Paris, France: Atlantis Press, 2021. http://dx.doi.org/10.2991/ahsr.k.211105.029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Husni, Elidahanum, Utari Septiana Putri, and Dachriyanus. "Chemical Content Profile of Essential Oil from Kaffir Lime (Citrus hystrix DC.) in Tanah Datar Regency and Antibacterial Activity." In 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021). Paris, France: Atlantis Press, 2021. http://dx.doi.org/10.2991/ahsr.k.211105.025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'PHARMA] Life Sciences' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography